Therapy Response and Outcome Explained by Leukemia Cell of Origin

Cancer Discov. 2020 Oct;10(10):1445-1447. doi: 10.1158/2159-8290.CD-20-1080.

Abstract

In this issue of Cancer Discovery, Cai and colleagues delineate a new mechanism that links cell of origin, the transcription factor EVI1, apoptotic priming, and therapeutic susceptibility in mixed lineage leukemia-rearranged acute myeloid leukemia. These findings establish a cell of origin-dependent program that may be leveraged by therapeutic combinations to overcome drug resistance in chemoresistant leukemias.See related article by Cai et al., p. 1500.

Publication types

  • Comment

MeSH terms

  • DNA-Binding Proteins
  • Histone Demethylases
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Myeloid-Lymphoid Leukemia Protein*
  • Transcription Factors

Substances

  • DNA-Binding Proteins
  • Transcription Factors
  • Myeloid-Lymphoid Leukemia Protein
  • Histone Demethylases